Objective: To determine whether the increase in plasma levels of C-Reactive Protein (CRP), a non-specifi c reactant in the acute-phase of systemic infl ammation, is associated with clinical severity of peripheral arterial disease (PAD).
Introduction
Laboratory and experimental evidence have shown that infl ammatory processes play a central role in the development, progression and outcomes of atherosclerosis. Several studies suggest that patients at high risk of developing atherothrombotic disease suffer from chronic systemic infl ammation. 1 More specifi cally, increased levels of C-Reactive Protein (CRP), a seric marker of systemic infl ammation, have been associated with a higher risk of: acute myocardial infarction or sudden death in patients diagnosed with either stable or unstable angina, 2 symptomatic ischemic coronary disease in elderly patients, 3 death caused by coronary disease 4 and fi rst episodes of myocardial infarction or cerebral ischemic stroke in otherwise apparently healthy people. 1 Likewise, some hypotheses propose that the seric concentration of CRP could have a predictive value in preclinical atherosclerosis as a molecular indicator of the severity of the disease. Indeed, recent research concludes that high-sensitivity measurements of CRP provide an adjunctive method for global assessment of cardiovascular risk, in addition to traditional screening methods. 5 Thus, CRP plasma levels would add information of prognostic value to that obtained from plasma lipid levels based on Framingham study-based criteria. 6 Peripheral Arterial Disease (PAD) includes all the clinical entities resulting from arterial blood fl ow obstruction, excluding coronary and intracranial vascular beds. In this paper, the focus is on PAD affecting just the lower extremities.
Currently, there are few data relating CRP levels to PAD. Evidence 7 is found suggesting that increased basal levels of CRP in otherwise healthy people are associated with a higher risk of intermittent claudication and peripheral surgical revascularization.
Objective
The aim of this study is to determine whether the increase in CRP concentration, a non-specific reactant in the acute-phase of systemic infl ammation that can be easily and reliably measured, is associated with clinical severity of PAD.
Material and Methods
A prospective cross-sectional study was designed in order to fi nd out a possible relationship between CRP plasma levels and the clinical severity of PAD in a target population of patients with PAD, in the south of Madrid in Spain with a population of 3 million. For this purpose, a random sample of the target population was used and they were classifi ed as described below, which allowed a prospective assessment of the inflammation markers in a well-established gradation according to the aggression of the disease at the time of presentation.
The study population was made up of 3370 patients diagnosed with PAD registered in the outpatient vascular laboratory database of this hospital. All patients were documented with, at least, a hemodynamic study with arterial Doppler of the lower extremities that demonstrated an ankle-brachial index lower than 0, 8.
With the purpose of evaluating the association between CRP plasma levels and the clinical form of PAD developed, three patient groups were formed as follows:
• Group 1: patients with symptomatic PAD in the lower extremities who did not require surgical revascularization • Group 2: patients with symptomatic PAD in the lower extremities who had undergone only one surgical revascularization procedure (either open or endovascular surgery) of the lower extremities (in the aorto-iliac or infra-inguinal area) before December 31st 2005 (A latent period of 12 months without an operation is considered to be a sign of no progression of the disease).
• Group 3: patients with symptomatic PAD in the lower extremities who had undergone two or more surgical revascularization procedures (either open or endovascular surgery) of the lower extremities ( in the aorto-iliac or infrainguinal area) in different areas or patients with symptomatic PAD in the lower extremities who needed another procedure in the same area with a delay of more than 12 months between procedures • (The aorto-iliac area is considered to be different from the infra-inguinal area, and this last one also considered to be a different area from that of the lower limbs).
The total population of 3370 patients were divided according to their clinical presentation into the three above-mentioned groups resulting in 2900, 380 and 90 patients respectively. The Neyman's affi xation was used to calculate the sample size needed for each stratus (N1, N2, N3). 8 For a fi xed relative error of 0.1 calculated for the average, the sample size had to be 51 patients. The affi xations were then calculated according to Neyman to calculate the size of each stratus: N1 = 23; N2 = 17; N3 = 10. Therefore, 330 patients were randomly chosen from the different groups: 150 from the fi rst group, 130 from the second and 50 from the third. All the patients who had had any infectious disease or other acute illness such as acute coronary or limb ischemia, and those who had undergone any surgical procedure within a 16-week period were excluded from the study, in order to control any possible bias by elevated CRP levels resulting due to these processes. Any patient with foot ulcers was also excluded.
Blood samples were taken from all of them, followed by standard blood processing and storing procedures. The plasma CRP levels along with the plasma lipidic profi le (total cholesterol levels, triglycerides and HDL, LDL and VLDL lipoproteins), the plasma homocystein concentration, serum creatinine level and the glycosylated hemoglobin level of each patient were determined. A complete blood count was done. Clinical history about the cardiovascular risk factors, associated medication and symptoms of ischemia were obtained from the patients through individual interviews. At the time of blood sampling, all patients were in a Rutherford category of three or minor.
The CRP plasma concentrations were determined by an automatic ultrasensitive immunoassay (Roche Diagnostics GMBH) with a lower-limit detection of 0.2 mg/L and a coeffi cient of variation of 4.2% in 4 mg/L and 6.3% in 1 mg/L.
The CRP plasma concentration median within each group was calculated along with the statistical signifi cance in the differences found between them by means of stratifi ed unifactorial analysis of multiple comparisons of medians according to Schaffé, who uses the F Distribution of Snedecor, which is not infl uenced by a lack of homogeneity within the groups. 8 The homogeneity within the groups was checked regarding CRP plasma levels and the following variables: age, smoking status, hypertension, diabetes, hyperlipidemia and lipidic plasma profi le, COPD, coronary heart disease, cerebrovascular disease, homocysteinemia, serum creatinine levels, LDH plasma levels, and leukocytes, neutrophils, lymphocytes and reticulocytes.
A multivariant analysis among groups was also performed to rule out possible confounding factors for the following variables: age, smoking status, hypertension, diabetes, hyperlipidemia and lipidic plasma profi le, COPD, coronary heart disease, cerebrovascular disease, homocysteinemia, serum creatinine levels, blood markers of acute infl ammation (leukocytosis, neutrophilia, basophilia, eosinophilia, monophilia, percentage of reticulocytes) and associated anti-infl ammatory medication (aspirin and trifusal prescribed for PAD and steroid and non-steroid anti-infl ammatory drugs prescribed for other diseases).
All the variable data were expressed as median ± standard deviation except the variable CRP, expressed as median [quartil25-quartil75].
A p-value Ͼ 0.05 was considered to be signifi cant. These results also show homogeneity between the groups relating to cardiovascular risk factors.
Results
The multivariate analysis made on the factors associated with PAD stages resulted in no significant differences for any variable. Table 2 displays plasma levels of specific markers of infl ammation and blood counts in each clinical group at the time of plasma CRP level testing. There were no differences between groups for any tested marker and the levels show that there was no acute infl ammatory process at the time of blood sampling that could have affected the study.
No difference was found between groups concerning associated medication that could have affected CRP plasma levels: statins, ACE-inhibitors, angiotensin receptor blockers and beta blockers.
Intragroup homogeneity test applied to CRP plasma levels and all the variables obtained from multivariate analysis among the groups show homogeneity in each group for all variables.
Once the intragroup homogeneity was tested the data of CRP plasma levels were analysed (Table 3) .
In the unifactorial analysis of multiple comparisons of medians according to Scheffé for CRP plasma levels, it was found that in each group, an F statistic value of 24.113 was obtained which showed a significant grade much lower than 0.05 (ca. 0.000), thereby demonstrating a statistically signifi cant difference between CRP plasma levels of the patients grouped according to the clinical severity of their PAD. This suggests, therefore, the existence of a consistent relationship between both variables.
As it can seen, median values of CRP plasma levels were increased in association with higher clinical severity of PAD (3.81 mg/L; 8.33 mg/L; 12.83 mg/L) ( Figure 1 ). These data indicate a direct relationship between CRP plasma levels and clinical severity of PAD.
Discussion
The data presented here allows the inference that there exists an association in patients with symptomatic PAD between their CRP plasma levels and the way the disease develops clinically. In previous studies the CRP basal levels in apparently healthy patients have already been linked to the risk of developing symptomatic PAD. 7 Therefore, the results obtained here allow widening of the previously acknowledged role of CRP as a marker of vascular risk, not only in the coronary and cerebral beds but also in the peripheral circu- lation, associating it directly with the severity and extension of PAD. From a more integrative perspective based upon the results of this study and those of previous studies, [1] [2] [3] [4] 7 it may be hypothesized that CRP could serve as a molecular marker of the presence and clinical severity of systemic atherosclerotic disease.
Studies trying to prove the role of CRP in cardiovascular risk assessment use "high-sensitive" CRP measurements since standard clinical assays for CRP typically have a lower detection limit of 1 to 3 mg/L. Thus, these assays lack sensitivity within the low-normal range and cannot be used effectively for vascular risk prediction. In recognition of this limitation, these epidemiological studies use "high-sensitivity" tests to determine CRP levels with excellent fi delity and reproducibility across the normal range. 9 In infl ammatory status, as in the symptomatic PAD that this study aims to prove, CRP levels are increased signifi cantly and thus standard CRP assays help in accurate measurement of the severity of the disease.
Non-specifi c infl ammatory markers increase in acute infection or trauma and in individuals with clinically apparent infl ammatory conditions such as rheumatoid arthritis or lupus. All the patients who had had any infectious disease or other acute illness such as acute coronary or limb ischemia within a 16-week period, and those suffering from chronic infl ammatory disease were excluded from the study. It was also ensured that the specifi c acute-phase infl ammatory cells and serum markers were similar between the three groups.
The mechanism of CRP's association with an increase in the risk and severity of atherosclerotic disease is only suggested by diverse hypotheses. It is believed that CRP, in addition to being a hepatic marker of systemic infl ammation, could have a procoagulant effect associated with its capacity to promote the expression of tissue factor. 10 Table 3 . Clinical severity of peripheral arterial disease according to C-reactive proteinplasma levels. Experimental studies suggest that CRP can induce activation of the complement system, 11 bind to human neutrophils, 12 be found in the endothelium of the blood vessels 13 and can be probably involved in the secretion of cellular adhesion molecules that play an important role in the leukocyte adhesion and migration across the vascular wall-a very important step in the beginning of atherosclerosis. 14 On the other hand, there are also hypotheses that suggest that low-grade infl ammation detected by CRP indicates a chronic infection process. Currently, there are cross-sectional and case-control studies that have reported elevated antibody titers against Helicobacter pylori, Chlamydia pneumoniae and Cytomegalovirus in patients with a high prevalence of heart disease. 15 It is also possible that the association between CRP and atherosclerotic disease is a product of cytokines such as interleukin-6 (IL-6) that promote leukocyte adhesion and stimulate CRP production. Studies have demonstrated the relationship between infl ammation and endothelial dysfunction and thereby the deregulation in nitric oxide metabolism. 16, 17 Although previous studies have shown positive associations between ankle-brachial index and measurements of hemostatic and infl ammatory markers, 18 there have been no known previous studies that have directly compared the relationship between CRP plasma levels in patients with symptomatic PAD and the severity in the chronological behaviour of the disease.
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This study has some limitations as it is crosssectional and thereby there is a diffi culty in determining whether the higher CRP levels are causally related to the clinical severity of PAD. However, this relationship reinforces the important role of the infl ammatory pathway in the form of presentation of PAD in the symptomatic states and not just in the case of underlying asymptomatic disease, where CRP is well-known as a predictor and marker of developing peripheral vascular disease. [19] [20] [21] [22] [23] [24] The second limitation is that the long-term effects of the surgical procedures, as could be in case of the infl ammatory changes at anastomotic sites, would be able to elevate the CRP plasma levels. Experimental in vivo and pathologic studies have shown that infl ammatory reaction in the atherosclerotic plaque is exponentially greater than that produced in the anastomosis by the vascular wall trauma.
In conclusion, plasma levels of CRP are associated not only with the presence of atherosclerosis but also with its clinical severity in the target population of this study. For universality of this conclusion more studies are required with a larger target population.
